shutterstock_80748427
News
Orna Therapeutics and Vertex Pharmaceuticals to develop next generation approaches for Sickle Cell Disease...
Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, has entered a three-year strategic research collaboration with Vertex Pharmaceuticals to utilize Orna’s novel and...
Antibody-drug conjugate receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK's GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for...
Araris enters collaboration with Chugai to develop next-generation ADCs
Araris, a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), has entered a Research Collaboration and Option to License Agreement (RCO) under...
